Clinical Trials Directory

Trials / Completed

CompletedNCT00127673

Comparison of Two Treatments for Post-Traumatic Stress Disorder

Effectiveness of PTSD Treatment: CBT Versus Sertraline

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
200 (actual)
Sponsor
Case Western Reserve University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study will compare the short- and long-term effectiveness of two different treatments for people with post-traumatic stress disorder.

Detailed description

Exposure to traumatic events, such as automobile accidents and assault, can cause individuals to develop persistent psychological difficulties such as post-traumatic stress disorder (PTSD). PTSD is an anxiety disorder characterized by avoidance, hyperarousal symptoms, and mental re-experiencing of the traumatic event. PTSD is a serious condition that may cause social and psychological impairment; therefore, safe and effective treatments are needed. Both CBT and antidepressant therapy have been shown to effectively treat PTSD symptoms; however, comparisons of the treatments are limited. This study will compare the short- and long-term effectiveness of CBT and the antidepressant sertraline. Participants will either be randomly assigned to CBT or sertraline, or they will be able to choose one of the two treatments, which will be given for 10 weeks, followed by 24 months of follow-up assessments. Participants in the CBT group will have 10 weekly sessions of therapy. During the therapy sessions, participants will be encouraged to confront their general fears and the memory of their trauma through repeated storytelling. Participants will also be encouraged to practice the techniques learned in therapy in everyday life. Participants in the antidepressant group will take sertraline daily for 10 weeks. These participants will be seen weekly by a psychiatrist who will offer general encouragement and support, monitor response to medication, and record any side effects participants may be experiencing. The medication may be adjusted according to a dosing schedule and based on the study doctor's judgment. At the end of 10 weeks, participants in the antidepressant group will have the choice of either tapering the medication gradually to minimize the chance of withdrawal symptoms or staying on the medication for up to 24 months. Participants who do not respond to their assigned or chosen treatment will be offered the other treatment for 10 weeks. Self-report scales and questionnaires will be used to assess participants' PTSD symptoms, depression, anxiety, and social functioning. These assessments will occur at 3, 6, 12, and 24 months after the study treatment period.

Conditions

Interventions

TypeNameDescription
DRUGSertralineThe dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
BEHAVIORALCognitive behavioral therapy (CBT)CBT will include 10 weekly sessions of individual cognitive behavioral therapy.

Timeline

Start date
2004-09-01
Primary completion
2011-08-01
Completion
2011-08-01
First posted
2005-08-08
Last updated
2022-05-24
Results posted
2022-05-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00127673. Inclusion in this directory is not an endorsement.